Efficacy and action mechanism of Imrecoxib in the treatment of axial spondyloarthritis

Trial Profile

Efficacy and action mechanism of Imrecoxib in the treatment of axial spondyloarthritis

Completed
Phase of Trial: Phase IV

Latest Information Update: 16 Nov 2016

At a glance

  • Drugs Imrecoxib (Primary) ; Celecoxib
  • Indications Ankylosing spondylitis
  • Focus Therapeutic Use
  • Sponsors Jiangsu Hengrui Medicine Co.
  • Most Recent Events

    • 12 Nov 2016 Status changed from recruiting to completed.
    • 02 Jun 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top